



## 27 **Summary**

28 Lipid droplets (LDs) are increasingly recognized as critical organelles in signalling events,  
29 transient protein sequestration and inter-organelle interactions. However, the role LDs play in  
30 antiviral innate immune pathways remains unknown. Here we demonstrate that induction of  
31 LDs occurs as early as 2 hours post viral infection, is transient, and returns to basal levels by  
32 72 hours. This phenomenon occurred following viral infections, both *in vitro* and *in vivo*.  
33 Virally driven LD induction was type-I interferon (IFN) independent, however, was  
34 dependent on EGFR engagement, offering an alternate mechanism of LD induction in  
35 comparison to our traditional understanding of their biogenesis. Additionally, LD induction  
36 corresponded with enhanced cellular type-I and -III IFN production in infected cells, with  
37 enhanced LD accumulation decreasing viral replication of both HSV-1 and Zika virus  
38 (ZIKV). Here, we demonstrate for the first time, that LDs play vital roles in facilitating the  
39 magnitude of the early antiviral immune response specifically through the enhanced  
40 modulation of IFN following viral infection, and control of viral replication. By identifying  
41 LDs as a critical signalling organelle, this data represents a paradigm shift in our  
42 understanding of the molecular mechanisms which coordinate an effective antiviral response.

## 43 **Introduction**

44 Lipid droplets (LDs) are storage organelles that can modulate lipid and energy homeostasis,  
45 and historically, this was considered their defining role. More recently, LDs have emerged as  
46 a dynamic organelle that frequently interact with other organelles and are involved in protein  
47 sequestration and transfer between organelles. LDs have also been demonstrated to act as a  
48 scaffolding platform to regulate signalling cascades, highlighting their diverse functions<sup>1-4</sup>.

49 The role of LDs in an infection setting has not been well studied, however, it has been  
50 demonstrated that LDs accumulate in leukocytes during inflammatory processes, and they are  
51 also induced in human macrophages during bacterial infections<sup>2</sup>. Multiple bacterial strains,  
52 including *Mycobacterium* spp., *Chlamydia* spp., *Klebsiella* spp. and *Staphylococcus* spp. are  
53 known to upregulate LDs very early following bacterial infection in both primary and cell  
54 culture macrophage models, and this has also been seen for a number of bacterial species in  
55 rodent macrophage cell lines<sup>5-7</sup>. Interestingly, *Trypanosoma cruzi* infection of macrophages  
56 also induces LDs, however, this response takes 6-12 days to occur following infection<sup>8</sup>.  
57 Bacterial- induced LD induction in immune cells has been shown to depend on toll-like

58 receptor engagement, mainly via TLR2 and TLR4, however, the role of LDs in the outcome  
59 of bacterial infection remains largely unknown, and the exact mechanisms for controlling LD  
60 induction remain elusive<sup>9,10</sup>. It has been suggested in recent work in the zebrafish model that  
61 embryos with higher levels of LDs are more protected from bacterial infections<sup>11</sup> and work  
62 in the *Drosophila* embryo has demonstrated that LDs can bind to histones which are released  
63 upon detection of intracellular bacterial LPS and act in a bactericidal manner<sup>12</sup>.

64 Interestingly, LD induction has been demonstrated to be a direct result of immune activation  
65 of macrophages by IFN- $\gamma$  in a HIF-1 $\alpha$  dependent signalling pathway<sup>13</sup>. *M. tuberculosis*  
66 acquires host lipids in the absence of LDs under normal conditions, however, IFN- $\gamma$   
67 stimulation of macrophages results in redistribution of host lipids into LDs where *M.*  
68 *tuberculosis* is unable to acquire them<sup>13</sup>. IFN- $\gamma$  induced LDs have also been shown to  
69 enhance expression of genes involved in LD formation and clustering in INS-1 $\beta$  cells. More  
70 importantly, pre-treatment of INS-1  $\beta$  cells with IFN- $\gamma$  markedly increased PIC-induced  
71 expression of antiviral genes (e.g. *Ifnb*, *Mx1*)<sup>14</sup>.

72 Although induction of LDs has been documented to occur mainly in macrophage models,  
73 following infection with bacteria, the ability of viral infection of cells to induce the same  
74 response remains relatively unexplored. Recently, viral infection of the positive-stranded  
75 RNA viruses, Sindbis and dengue virus, was shown to induce LD formation in the cells of  
76 mosquito midgut for the first time<sup>15</sup>. This LD induction was mimicked via synthetic  
77 activation of the antiviral innate pathways, Toll and IMD, similar to the induction of  
78 bacterial-induced LDs. Although it is known that activation of early innate signalling  
79 pathways appears to induce LDs in the presence of bacteria, and in the mosquito midgut  
80 when virally infected, the mechanisms at play remain unknown, as does the functional  
81 outcome of this LD induction. Here we show for the first time that LDs are induced early  
82 following both RNA and DNA viral infection and that this induction is transient in nature and  
83 facilitates an effective antiviral response.

84

## 85 **Results**

### 86 **Lipid droplets are induced early following viral infection**

87 To determine if LD induction following viral infection is a common phenomenon in  
88 mammalian cells, we infected cultured cells with viruses from 3 different viral families.  
89 HSV-1, influenza and ZIKV all induced upregulation of LDs at 8 hours following infection,  
90 as seen via microscopy (Fig. 1 and Supplementary Fig. 1). Influenza infection of THP-1  
91 monocytes with either the virulent PR8 strain or the more attenuated X-31 strain induced a  
92 6.5-fold increase in LD numbers (Fig. 1A). Primary human foetal immortalised astrocytes  
93 were assessed for their ability to upregulate LDs when infected with the neurotropic viruses  
94 ZIKV and HSV-1. Astrocytes were seen to have a high average basal level of LDs per cell  
95 (approximately 15 per cell) (Fig. 1B and 1C), which was significantly increased by 3.9 and 4-  
96 fold following infection of these cells with either ZIKV, or HSV-1, respectively (Fig.1B and  
97 1C). *In vivo*, we examined lung sections taken from both mock and influenza A infected  
98 C57BL/6 mice. A clear increase in the presence of large LDs was detected near the  
99 bronchioles in the Influenza A infected mice, which was absent in the mock infected mice at  
100 both 1- and 3-days post infection (Fig. 1D and Supplementary Fig. 1B).

101 HSV-1, ZIKV and influenza viruses enter their host cell by either plasma membrane fusion or  
102 following endocytosis, prior to the release of their genomic material<sup>16,17</sup>. In order to  
103 determine if pattern recognition receptor (PRR) detection of nucleic acid alone would drive  
104 an induction of LDs in cells, we stimulated these cells with the synthetic viral mimics,  
105 dsRNA (poly I:C, known to mimic viral RNA pathogen associated molecular patterns  
106 (PAMPs), and activate the RNA sensors RIG-I and TLR3) or dsDNA (poly dA:dT, known to  
107 mimic DNA viral PAMPs, and activate cytosolic DNA sensors). As can be seen using  
108 confocal microscopy in Fig. 2A, rhodamine labelled dsRNA and dsDNA clearly induced an  
109 upregulation of LDs in primary immortalised astrocytes. To determine if this was a common  
110 phenomenon across cell types, similar experiments were performed in primary murine foetal  
111 astrocytes, THP-1 monocytes/macrophages, HeLa cells and primary murine embryonic  
112 fibroblasts (MEFs). Astrocytes were seen to have a high basal level of LDs, with primary  
113 foetal murine astrocytes and immortalized human astrocytes having an average of 22 and 18  
114 LDs per cell respectively; this contrasted with the lower levels of LDs seen in other cell  
115 types, which ranged from 6 to 9 LDs per cell (Fig. 2B). All cell types stimulated with either  
116 of the viral mimics upregulated LDs at 8 hrs (Fig 2B and S2). Stimulation of cells with  
117 dsRNA resulted in LD upregulation fold changes ranging from 4.1-fold in the MEFs to 9.5-  
118 fold in the THP-1 macrophages (Fig. 2B). Similarly, dsDNA stimulation resulted in a 4.1-  
119 fold induction in HeLa cells and, up to a 10.2-fold induction in the THP-1 monocyte cells

120 (Fig. 2A). This increase was also shown to be independent of whether FCS was in the culture  
121 media (Fig. S2).

122 Although LD numbers increased in all cell types, the average size of LDs did not (Fig. 2C).  
123 The average basal size of LDs was consistent across most cell types, with a diameter range of  
124 280-400 nm (Fig. 2C); however, THP-1 macrophages had a starting average basal LD size of  
125 3100 nm, which did not increase following stimulation with either dsRNA or dsDNA. In  
126 contrast, all other cell types had an increased average LD size at 8 hours following dsRNA  
127 stimulation, ranging from a 2-fold increase in THP-1 monocytes to a 5.3-fold increase in  
128 HeLa cells, with similar size increases observed following dsDNA stimulation also (Fig. 2C).  
129 The average size of LDs in the primary immortalised astrocytes following stimulation with  
130 viral mimics ranged from 760 to 910 nm (Fig. 2C), however as can be seen in Fig. 2D, there  
131 was a significant increase in the number of LDs greater than 1000 nm in these cells, and also,  
132 a substantial increase in LDs less than 200 nm, which are referred to as nascent LDs <sup>18</sup>.  
133 Nascent LDs made up 24% and 23% of the LD population following dsRNA and dsDNA  
134 stimulation respectively, in comparison to only 13% in control-treated cells, perhaps  
135 indicating that nucleic acid stimulation drives both the generation of new LDs as well as the  
136 growth of existing LD populations.

137

138 **Lipid Droplet accumulation is transient following detection of intracellular nucleic acids**  
139 **and follows a similar time course to interferon mRNA upregulation.**

140 To define the dynamics of LD induction following the detection of nucleic acids in the cells,  
141 we set up a time course series to quantify the speed and longevity of this response. LDs were  
142 upregulated as early as 2 hours following either dsRNA or dsDNA stimulation (Fig. 3A and  
143 3B), stayed significantly upregulated for 48 hours post-stimulation and, returned to baseline  
144 levels by 72 hours. The average LD number per cell increased from approximately 17 to 28-  
145 40 LDs per cell at 2 hours post-stimulation, depending on the stimulation type. Interestingly,  
146 dsRNA or dsDNA stimulated cells reached a maximum LD induction between 4-8 hours,  
147 however, dsRNA stimulated cells showed an initial decrease in LD number at 24hrs and, a  
148 subsequent increase at 48hrs, prior to returning to baseline levels at 72 hrs, indicating a  
149 biphasic response, which was not seen following stimulation of the cells with dsDNA.  
150 Average LD size per cell was also shown to transiently increase over the same time course

151 (Supplementary Fig. 3). Interestingly, the induction of LDs coincided with the production of  
152 type-I and -III IFN mRNAs in the astrocyte cells (Fig. 3C and 3D), where peak IFN mRNA  
153 induction was seen at 8 hours post dsDNA stimulation, but at 24 hours after dsRNA  
154 stimulation. IFN mRNA levels showed a trend of returning to basal levels after 72 hours.

155

### 156 **Increasing cellular LD numbers acts to enhance the type I and III IFN response to viral** 157 **infection**

158 We have previously demonstrated that loss of cellular LDs impacts the host cell response to  
159 viral infection *in vitro*<sup>19</sup>. To determine if the upregulation of LDs following viral infection  
160 plays an anti-viral role in the cell, we initially established a LD induction model in the  
161 primary immortalised astrocytes. Addition of oleic acid to cells has previously been shown to  
162 enhance LDs minutes following treatment in Huh-7 cells<sup>20</sup>. As can be seen in figure 4A and  
163 4B, the addition of 500  $\mu$ M of oleic acid to astrocytes in cell culture for 16 hours increased  
164 the average LD number from approximately 16 to 43 per cell. Furthermore, despite the  
165 increase in cellular LD numbers, stimulation of cells with either dsRNA or dsDNA was able  
166 to further upregulate cellular LD levels (Fig 4C and S4). Interestingly, LD upregulation was  
167 accompanied by significantly enhanced IFN transcription and translation (Fig. 4D, 4E, 4F  
168 and 4G). In the presence of oleic acid enhanced LD numbers, a significant increase in IFN  
169 mRNA transcription was seen (Fig. 4D and 4E), although, no increase at the protein level  
170 (Fig. 4F and 4G). Addition of dsRNA to the cells in the presence of enhanced LDs (oleic acid  
171 treated) showed a 2-fold increase in IFN- $\beta$  and IFN- $\lambda$  mRNA at 8 hrs, which was  
172 accompanied by a 2-fold increase in the mRNA of the interferon stimulated gene, viperin.  
173 However, increases in the transcriptional level for these genes were only observed at 24 hours  
174 for IFN- $\lambda$  and viperin (2 and 2.6-fold respectively; Fig. 4D and 4E). Addition of dsDNA to  
175 cells with an enhanced LD content did not increase the IFN- $\beta$  transcriptional response,  
176 however, a small but significant increase in IFN- $\lambda$  and viperin mRNA was observed at both 8  
177 and 24 hours post-stimulation (1.5 and 2-fold respectively at 8 hours, and 2.5 and 2-fold at 24  
178 hours (Fig. 4D and 4E)). In confirmation of the transcriptional upregulation of IFNs,  
179 significantly enhanced protein levels could be seen for both IFN- $\beta$  and IFN- $\lambda$  following  
180 either dsRNA or dsDNA stimulation of primary immortalised astrocytes with oleic acid  
181 induced LDs, in comparison to controls (Fig. 4F and 4G). The presence of upregulated LDs

182 was able to significantly enhance the production of IFN- $\beta$  and IFN- $\lambda$  protein by as much as  
183 2.6 and 3.6-fold in the presence of dsRNA and 2.0 and 2.1-fold in the presence of dsDNA.  
184 Interestingly, the production of both IFN- $\beta$  and IFN- $\lambda$  was much greater following  
185 stimulation with dsDNA in comparison to dsRNA in the astrocyte, with IFN- $\lambda$  being the  
186 dominantly expressed IFN species.

187 Next, we assessed the host antiviral response to viral infection, in the presence of enhanced  
188 LDs. LD loaded cells, when challenged with ZIKV demonstrated a 3.5-fold increase in the  
189 production of IFN- $\beta$  mRNA at 24 hours and a small but significant increase of 1.7-fold at 48  
190 hours post-infection when compared with control infected cells (Fig. 5A). IFN- $\lambda$  followed a  
191 similar trend showing a 3.3 and a 2.2-fold increase at 24 and 48 hours respectively (Fig. 5A),  
192 and a 5-fold increase in IFN- $\lambda$  mRNA at just 6 hours post-infection. Interestingly, when  
193 looking at the production of a key antiviral signalling and LD resident protein, viperin, cells  
194 with enhanced LDs showed a significant increase in mRNA at 6, 24- and 48-hours post ZIKV  
195 infection. Cells infected with the dsDNA virus, HSV-1 also showed a similar trend, where the  
196 production of mRNA for both IFN- $\beta$  and IFN- $\lambda$  as well as viperin were enhanced in cells pre-  
197 treated with oleic acid (Fig. 5B). These results correlated well with a reduced viral load of  
198 both ZIKV and HSV-1 at 24 hours (6.3-fold and 2.3-fold for ZIKV and HSV-1 respectively)  
199 (Fig. 5C and 5D) and at 48 hours post infection (1.4-fold decrease in ZIKV mRNA and a 2.6-  
200 fold decrease in HSV-1 (Fig. 5C and 5D)). This reduction in viral load for ZIKV coincided  
201 with a significantly enhanced level of both IFN- $\beta$  and IFN- $\lambda$  production by the astrocytes  
202 with upregulated LDs (Fig. 5E).

203

## 204 **Lipid droplets accumulate in response to IFN, despite initial accumulation being type-I** 205 **IFN independent**

206 Detection of aberrant nucleic acid in cells drives a rapid interferon response<sup>21</sup>. In order to  
207 determine if LD induction following the detection of intracellular nucleic acids required the  
208 production of IFN, we stimulated Vero cells, which lack the ability to produce IFN due to  
209 spontaneous gene deletions<sup>22,23</sup>, with both dsRNA and dsDNA. Both LD number and size  
210 were significantly upregulated in Vero cells at 8 hours post-stimulation (Fig. 6A, 6B and  
211 Supplementary Fig. 5), indicating that this is an IFN independent event. As can be seen in

212 figure 6C and 6D, LDs were significantly induced by up to 4.5-fold following interferon  
213 stimulation. To show this in a more physiologically relevant setting, astrocyte cells were  
214 treated with dsRNA and dsDNA and left to produce IFNs for 24 hours, and their conditioned  
215 media was removed and placed on untreated astrocyte cells. Conditioned media from cells  
216 stimulated with dsRNA was also shown to induce LDs by 6.3-fold, a similar level to that  
217 induced by 1000 U/mL of IFN- $\beta$  (Fig 6E). Interestingly, conditioned media from cells  
218 stimulated with dsDNA showed no increase in LD numbers (Fig. 6E), perhaps indicating the  
219 presence of an inhibitor of LD induction. To confirm that it was the presence of secreted  
220 IFNs in the conditioned media alone, that was driving the production of LDs, we took  
221 conditioned media from both dsRNA and dsDNA stimulated astrocytes and Vero cells at 24  
222 hours following stimulation and placed it back onto untreated cells. As the Vero cells lack the  
223 ability to secrete type-I IFNs, we expected to see no induction of LDs in cells receiving  
224 conditioned culture media from these cells, which we observed (Fig. 6F). The induction of  
225 LDs was only driven with the addition of dsRNA conditioned media removed from astrocytes  
226 and placed onto both naive astrocytes and Vero cells. Interestingly, the addition of  
227 conditioned culture media from Vero cells stimulated with dsDNA onto untreated astrocytes  
228 cells showed a 2.7-fold decrease in the average number of LDs per cell relative to control  
229 untreated cells (Fig. 6F). Perhaps, further demonstrating the presence of a secreted negative  
230 regulator of LD biogenesis following dsDNA stimulation of astrocytes.

231

### 232 **LD Induction Following Nucleic Acid detection is EGFR Mediated**

233 Phospholipase A2 (PLA<sub>2</sub>) is an enzyme known to be a key player in LD biogenesis, where it  
234 catalyses the hydrolysis of glycerophospholipids to release fatty acids from phospholipid  
235 membranes which are then sequestered into the ER membrane leading to the maturation and  
236 budding off of mature LDs<sup>18</sup>. Astrocyte cells were treated with AACOCF<sub>3</sub>, a well-described  
237 inhibitor of PLA<sub>2</sub>,<sup>24</sup> and their ability to induce LDs was assessed. AACOCF<sub>3</sub> was able to  
238 inhibit LD biogenesis post serum starvation (Fig. S6A and S6B), confirming that natural LD  
239 biogenesis in astrocytes requires PLA<sub>2</sub> activation. To assess whether LD induction following  
240 recognition of viral mimics also follows a PLA<sub>2</sub> driven mechanism, cells were treated with  
241 AACOCF<sub>3</sub> prior to stimulation. Inhibition of PLA<sub>2</sub> did not inhibit the induction of virally  
242 induced LDs in the primary immortalized astrocyte cells (Fig. 7A and 7B). EGFR  
243 engagement has previously been shown to control LD upregulation in colon cancer<sup>25</sup>. To



244 assess whether EGFR was important in LD biogenesis following viral mimic stimulation,  
245 primary immortalized astrocyte cells were treated with AG-1478, a well-described tyrosine  
246 kinase inhibitor of EGFR<sup>26</sup> and stimulated with dsRNA and dsDNA to evaluate LD  
247 induction. Astrocyte cells treated with AG-1478 demonstrated no induction of LDs after  
248 stimulation with dsRNA or dsDNA, however, AG-1478 did not inhibit the induction of LDs  
249 following oleic acid treatment, with LDs being induced approximately 5-fold (Fig. 7C and  
250 7D). Similarly, the treatment of MCF-7 cells (known to lack EGFR<sup>27</sup>), also resulted in no  
251 upregulation of LDs following stimulation with viral mimics but was able to upregulate LDs  
252 in the presence of oleic acid (Supplementary Fig. 7A and 7B). However, the inhibition of  
253 EGFR did not alter LD biogenesis post serum starvation (Fig. 7E), indicating that the EGFR  
254 receptor is able to mediate the induction of viral mimic driven LDs, but not natural biogenesis  
255 of LDs in astrocytes. Further downstream analysis also demonstrated that the EGFR mediated  
256 induction of virally driven LDs relies on subsequent PI3K activation in the cell (Fig. S7).

257 A time course of LD induction in cells treated with AG-1478 demonstrated that at 8 hours,  
258 there is no LD induction, confirming that the initial upregulation of LDs following nucleic  
259 acid stimulation is dependent on EGFR. However, at 24 hours post-stimulation, there was a  
260 2.5-fold increase in LD numbers in dsRNA stimulated cells, but not in dsDNA stimulated  
261 cells (Fig. 7F). At 48 hours post-stimulation, a similar trend was observed with a 4-fold  
262 induction in the dsRNA stimulated cells, but again no LD induction in the dsDNA stimulated  
263 cells (Fig. 7F). This result may explain the biphasic expression pattern of LDs seen following  
264 dsRNA stimulation of astrocytes, but not dsDNA stimulation (Fig. 3B), particularly if the  
265 second wave of LD induction is not dependent on EGFR. To assess this, we treated primary  
266 immortalised astrocyte cells with AG-1478 to inhibit EGFR and stimulated them with IFN- $\beta$   
267 and analysed their LD numbers after 16 hours. There was no significant difference in the  
268 upregulation of LDs of control cells compared with cells treated with AG-1478 when  
269 stimulated with IFN- $\beta$  indicating EGFR does not play a role in the upregulation of LDs  
270 induced with IFN stimulation (Fig. 7G).

271

## 272 **Inhibition of EGFR driven LDs impacts IFN production and attenuates viral infection**

273 We next wanted to understand the relationship between viral-induced EGFR driven LD  
274 biogenesis and the regulation of IFN mRNA. Primary immortalised astrocytes were pre-

275 treated with AG-1478 prior to being stimulated with dsRNA and dsDNA, and their ability to  
276 upregulate IFN mRNA assessed. Both IFN- $\beta$ , IFN- $\lambda$  and viperin mRNA levels were  
277 significantly downregulated at 8 hrs post nucleic acid treatment, with little change being  
278 present at 24 hrs post-stimulation (Supplementary Fig. 8A). However, the results were more  
279 pronounced when comparing IFN mRNA induction following both ZIKV and HSV-1  
280 infection. Inhibition of EGFR driven LDs did not impact the ability of ZIKV or HSV-1 to  
281 enter astrocytes, as evidenced by the comparisons of the 6 hour time points for both viruses  
282 (Fig. 8A and 8B); however viral replication was enhanced by as much as 26 and 24-fold at 24  
283 hrs post infection, and 2 and 24-fold at 48 hours post-infection with ZIKV and HSV-1  
284 respectively. Additionally, heightened viral nucleic acid levels corresponded to significantly  
285 lowered mRNA levels of IFN- $\beta$  at both the 24 and 48 hr time points for ZIKV and HSV-1  
286 infection (Fig. 8C and 8D) as well as significantly reduced IFN- $\lambda$  mRNA levels for ZIKV at  
287 both time points, and at 24 hours post-infection following HSV-1 infection. There was no  
288 IFN- $\lambda$  expression observed at 48 hrs following HSV-1 infection. The production of both type  
289 I and III IFN mRNA levels also corresponded to the production of mRNA levels for the  
290 interferon stimulated gene viperin, with significantly lowered mRNA levels seen in cells  
291 treated with the EGFR inhibitor prior to viral infection. These results are indicative of a  
292 reduced ability of the cell to produce IFN following viral infection when LD induction is  
293 inhibited using the EGFR kinase inhibitor, AG-1478.

294

## 295 **Discussion**

296 Lipid droplets are well known for their capacity as lipid storage organelles, however, more  
297 recently, they have emerged as critical organelles involved in numerous other biological  
298 functions. LD biology is an emerging field, with recent discoveries describing roles for LDs  
299 in multiple signalling and metabolic pathways as well as protein-protein and inter-organelle  
300 interactions<sup>1,3,4</sup>. LDs are now considered an extremely dynamic organelle involved in  
301 facilitating multiple cellular pathways and responses, however, their role in immunity  
302 remains relatively unexplored. We have previously shown that loss of LD mass impairs the  
303 antiviral response, and enhances viral replication<sup>19</sup>, however, the dynamic induction of LDs  
304 and the mechanism responsible for this, as well as their role in the innate immune signalling  
305 response, has not previously been characterised.

306 It has previously been described that the accumulation of LDs can occur in leukocytes during  
307 inflammatory processes, and that LDs are induced by a number of bacterial infections in  
308 macrophages (reviewed in <sup>2</sup>). The mechanisms behind such induction have been shown to be  
309 dependent on toll-like receptor engagement, however, their role in the outcome of bacterial  
310 infection is not known, and the exact mechanisms required for their induction remains elusive  
311 <sup>2</sup>. Recently, a role for LDs in the antiviral response was proposed for the mosquito, when  
312 viral infection was shown to induce LD formation in the cells of the midgut <sup>15</sup>. As this is a  
313 phenomenon that has never been observed in mammalian biology, we sought to understand  
314 how and why LDs were induced following viral infection.

315 We analysed the dynamic induction of LDs post activation of innate signalling pathways in a  
316 number of cell types, both primary and non-primary, to assess their ability to induce LDs  
317 upon infection. LDs were induced upon infection with ZIKV, influenza or herpes simplex  
318 virus-1 (Fig. 1A, B & C) in an *in vitro* setting, as well as early *in vivo* following influenza  
319 infection in a murine model (Fig. 1D). Interestingly, members of the Flaviviridae family of  
320 viruses (HCV, ZIKV and dengue) have previously been demonstrated to deplete LDs by  
321 utilising fatty acids to facilitate aspects of their viral life cycle <sup>28,29</sup>, with HCV and Dengue  
322 also utilising LDs as a platform for viral assembly, where they induce their lipolysis, and  
323 manipulate their biogenesis (reviewed in <sup>30</sup>). Recently, Laufman *et al* (2019) also  
324 demonstrated a relationship for enteroviruses with LDs, where replication complexes were  
325 shown to tether to LDs via viral proteins, to subvert the host lipolysis machinery, enabling the  
326 transfer of fatty acids from LDs and leading to the depletion of LDs in infected cells <sup>31</sup>.  
327 Interestingly, these studies were predominantly performed at late time points post viral  
328 infection *in vitro*, when viral replication is established. We were able to show a significant  
329 upregulation of LDs in primary astrocytes infected with ZIKV (a member of the *Flaviridae*  
330 virus family) at 8 hours post-infection, but could also see an observable down regulation of  
331 LDs at 2-3 days post infection of the virus (Supplementary Fig. 9), indicating that it is not a  
332 cell type specific response, but rather a function of viral replication at later time points. To  
333 better examine the induction of LDs in the absence of viral antagonism of the early innate  
334 immune response, we analysed LD dynamics in response to synthetic dsRNA and dsDNA  
335 viral mimics (Fig. 3) where it was clearly observed that these PAMPs were able to elicit a  
336 rapid upregulation of LDs as early as 2 hours post transfection, which peaked at around 8  
337 hours, and returned to baseline by 72 hours post stimulation. This in part corresponds to what  
338 Barletta *et al* (2016) demonstrated in their mosquito model, where LD accumulation was

339 mimicked via synthetic activation of the Toll and IMD antiviral innate pathways,<sup>15</sup> leading to  
340 the hypothesis that the accumulation of LDs may be an important antiviral response in the  
341 mosquito. It is interesting to note, that the number, size and composition of LDs vary greatly  
342 within cells in a homogenous population as well as in different cell types<sup>32</sup> and although all 5  
343 cell types examined in this study were able to induce LDs upon activation of these pathways,  
344 the degree in which they could achieve this differed (Fig. 2B). Furthermore, the average size  
345 of LDs in different cell types was also shown to increase with the exception of LDs from  
346 THP-1 macrophages (A cell type that already displays a large average size of LDs without  
347 prior stimulation), perhaps demonstrating that there is an optimal size range for LDs in  
348 respect to their functional importance following a viral infection.

349 Astrocytes are well known for their fast type I interferon response which can be protective  
350 from *flavivirus* infection and virus-induced cytopathic effects<sup>33,34</sup>. Astrocytes also have a  
351 very robust type-III IFN response which contributes to their ability to be refractory to HSV-1  
352 infection<sup>35,36</sup>. We were able to demonstrate that LD induction correlated with the production  
353 of both type I and III IFN, and that when impeded it significantly impacted the transcriptional  
354 IFN response in these cells. Additionally, when cellular LD numbers were enhanced *in vitro*,  
355 cells produced significantly higher secreted levels of both type I and III IFNs, which  
356 coincided with a significant drop in viral load in the infected cells. Together this suggests that  
357 the initial production of LDs following viral infection may play a significant role in limiting  
358 early viral replication, perhaps through an enhanced antiviral state in the cell. Interestingly,  
359 we were also able to demonstrate that dsRNA, and not dsDNA driven LDs were induced in a  
360 bi-phasic manner (Fig. 3), with the second wave likely being induced in an autocrine or  
361 paracrine manner following IFN secretion.

362 LDs are known to be induced via multiple mechanisms, with common LD biogenesis  
363 involving the accumulation of neutral lipids (most commonly TAG and sterol esters) between  
364 the bilayers of the ER membrane, leading to the budding off of nascent LDs into the  
365 cytoplasm<sup>37,38</sup>. Several proteins are involved in LD biogenesis in mammalian cells, including  
366 PLA<sub>2</sub>, perilipins (PLINs), triacylglycerol (TAG) biosynthetic enzymes, fat-inducing  
367 transmembrane proteins (FIT1 and FIT2), SEIPIN and fat-specific storage protein 27 (FSP27)  
368<sup>39</sup> as well as some evidence of additional proteins involved in membrane dynamics (coatamer  
369 protein 1, SNAREs, Rabs and atlastin)<sup>40</sup>. Here we demonstrate that virally induced LDs have  
370 a different biogenesis mechanism to the normal homeostatic LD biogenesis, and that their

371 production was driven independently of type-I IFN, however, both type-I and -III IFNs were  
372 able to stimulate the induction of LDs in astrocyte cells (fig. 6). There have been previous  
373 reports of Type- II IFNs (IFN- $\gamma$ ) inducing LDs during a Mycobacterium infection <sup>13</sup>,  
374 however, to our knowledge there have been no reports of other interferon species activating  
375 LD upregulation. Interestingly, we found that both EGFR and PI3K, but not PLA<sub>2</sub>, were  
376 driving the induction of LDs following viral infection, however this was not the case for LDs  
377 induced by IFNs (Fig. 7, Supplementary Fig. 7). EGFR has also previously been shown to  
378 elevate LD numbers in human colon cancer cells <sup>25</sup>. Additionally, increases in LDs were  
379 blocked by inhibition of PI3K/mTOR pathways, supporting their dependency on selected  
380 upstream pathways. This fits with our findings that EGFR engagement plays a role in the  
381 induction of virally induced LDs. As mentioned above, we also observed a bi-phasic  
382 induction of LDs following dsRNA stimulation, which was firstly mediated by EGFR, in an  
383 interferon independent mechanism, with a second wave of LDs being IFN inducible (fig. 4).  
384 It is interesting that this phenomenon was not observed following stimulation of cells with  
385 dsDNA, potentially indicating slightly different biogenesis pathways, or alternately the co-  
386 induction of a negative regulator of LD biogenesis. Previous seemingly contradictory work  
387 has identified both an inhibitory and stimulatory role for EGFR in type-I IFN production <sup>41</sup>  
388 <sup>42,43</sup>.

389 We have shown that the upregulation of LDs following a viral stimulus plays an antiviral role  
390 in the cell; and our work has demonstrated that this upregulation contributes to a heightened  
391 type I and III interferon response *in vitro*. However, the exact mechanisms involved in this  
392 heightened antiviral state still remain to be elucidated. One possibility is that the LD is being  
393 utilised as a platform for protein sequestration that contributes to an enhanced IFN response.  
394 Previous work from our team has extensively described the host protein, viperin as having  
395 both broad and specific anti-viral properties, which are largely dependent on its localization  
396 to the LD <sup>44-47</sup>. Viperin's presence on the LD has been shown to significantly enhance the  
397 production of type I IFN following engagement of dsDNA receptors, as well as the TLR7/9  
398 receptors <sup>47,48</sup>. It is plausible that there may still be undiscovered antiviral effectors that  
399 require LD localisation.

400 There is an expanding appreciation for the roles of lipids in the antiviral response during  
401 infection, in particular, how they can contribute to the inhibition of viral infections. Lipids  
402 have been shown to play numerous roles in activation and regulation of immune cells such as

403 T lymphocytes and macrophages<sup>49</sup>. Recently, a mechanism was described for the activation  
404 of macrophages through the release of a distinct class of extracellular vesicles, which are  
405 loaded with fat derived directly from adipocyte LDs<sup>50</sup>. As well as having a signalling role in  
406 activating immune cells, certain species of lipids have been shown to modulate immune  
407 responses. Polyunsaturated fatty acids (PUFAs) are precursors for the synthesis of numerous  
408 bioactive lipid mediators, such as eicosanoids and specialized pro-resolving mediators which  
409 are released from various immune cell types to modulate immune responses<sup>51-53</sup>. The PUFA  
410 lipid mediator D1 (PD1) has also been demonstrated to inhibit IAV infection in cultured cells  
411<sup>54</sup>. It is also important to note that LD populations both between cells and within a cell are  
412 diverse, and can consist of different sizes, numbers and distinct protein or lipid compositions.  
413 However, the reason for LD diversity is still unclear<sup>32,55-57</sup>. Lipidomics is a growing field  
414 and could be utilised to investigate the role and composition of specific subsets of LDs within  
415 cells both prior to, during and following viral infection, to give further insight into whether  
416 changes within the lipidome assist in driving an antiviral response.<sup>54</sup>

417 The early induction of LDs following a viral infection acts to aid the antiviral host response  
418 by enhancing the production of interferon. Multiple viruses have been demonstrated to usurp  
419 host cell LDs to facilitate their replication cycles, and it is possible that this may also  
420 represent a subversion mechanism to disrupt early antiviral signalling, however further work  
421 is required to unravel these intersections. LDs are now considered an extremely dynamic  
422 organelle involved in the facilitation of multiple cellular pathways and responses, and it is  
423 now clear that they are also involved in a pro-host response to viral infection.

424

## 425 **Acknowledgements**

426 This work was funded by a La Trobe University Research Focus Area grant, as well as a  
427 NHMRC ideas grant (APP1181434) to K.J.H. and D.R.W.. L.W. is funded by an ARC Future  
428 Fellowship, D.W. is funded by an ARC DECRA. The authors would like to acknowledge the  
429 La Trobe University Microscopy Platform.

## 430 **Author Contributions**

431 E.A.M. performed the majority of the experiments; M.D. and W.C. assisted in *in vitro*  
432 influenza studies, and L.W. performed the murine influenza *in vivo* studies. RO assisted in  
433 the isolation of murine astrocytes, and K.M.C. assisted in experiments involving MEFs,  
434 K.J.H. was responsible for the overall study design, with E.A.M., D.R.W. and K.M.C. also  
435 assisting in experimental direction. K.J.H. and E.A.M. wrote the manuscript; all authors  
436 commented on the manuscript.

## 437 **Declaration of Interests**

438 The authors declare no competing interests

439

## 440 **Figure Titles and Legends**

### 441 **Figure 1. Lipid Droplets accumulate in response to IAV, ZIKV and HSV-1 infections**

442 (a) Human THP-1 monocytes were infected with two different strains of influenza- PR8 and  
443 X-31 at an MOI 5 and (b) Primary immortalised astrocyte cells were infected with either the  
444 ZIKV strain MR766 or (c) HSV-1 at MOI 5 and stained with Bodipy (409/505) to visualise  
445 LDs and DAPI to visualise the cell nuclei. Influenza virus was detected with a  $\alpha$ NS2  
446 antibody, ZIKV RNA was detected using an anti-3G1.1 and 2G4 dsRNA antibody and HSV-  
447 1 was detected using the anti-HSV-1 antibody ab9533. Greater than 200 cells were analysed  
448 in each case using ImageJ analysis software, sourced from two independent biological  
449 replicate experiments Bars, 15 $\mu$ m. (d) C57BL/6 mice were either mock infected or infected  
450 with 10<sup>4</sup> PFU of influenza A virus for 24 or 72 hours prior to removal of both lung lobes for  
451 immunofluorescence analysis of LDs via Bodipy staining. Bars, 500 $\mu$ m. (data is represented  
452 as mean  $\pm$  SEM, n = 200 cells or n = 2 mice. \*\*\*\*=p<0.0001, Student's t-test)

453

### 454 **Figure 2. Detection of intracellular dsRNA and dsDNA initiates accumulation of LDs in** 455 **multiple cell types**

456 (a) Primary immortalised human astrocyte cells stimulated with dsRNA and dsDNA tagged  
457 with Rhodamine for 8hrs and stained with Bodipy (409/505) to visualise LDs and DAPI to  
458 visualise the cell nuclei. Cells were imaged on a Nikon TiE microscope. Original

459 magnification is 60X. Bar, 50µm (b) Average number of LDs per cell and (c) average LD  
460 sizes (diameters) were analysed from greater than 200 cells in a range of cell types, using  
461 ImageJ analysis software (n=2 biological replicates). (d) LD size distribution in primary  
462 immortalised astrocyte cells stimulated with either dsDNA or dsRNA for 8 hours. Bar, 15µm.  
463 Data is represented as mean  $\pm$  SEM, greater than 300 cells; n=3 biological replicates  
464 \*= $p$ <0.05, \*\*= $p$ <0.01, \*\*\*= $p$ <0.001, \*\*\*\*= $p$ <0.0001, Student's t-test.

465

466 **Figure 3. Lipid Droplet accumulation is transient following detection of intracellular**  
467 **nucleic acids**

468 (a) Primary immortalised astrocyte cells were stimulated with dsRNA and dsDNA and were  
469 fixed at regular time points until 72 hours post stimulation. Cells were stained with Bodipy  
470 (409/505) to visualise LDs and DAPI to visualise the cell nuclei. Bar, 50µm (b) Average  
471 number of LDs per cell were analysed from all time points using ImageJ analysis software.  
472 Greater than 200 cells were analysed over 3 separate biological replicates. (c and d) Primary  
473 immortalised astrocyte cells were stimulated with dsRNA and dsDNA and RTq-PCR was  
474 utilised to quantify IFN- $\beta$  and IFN- $\lambda$  mRNA up to 72 hours post stimulation. Data is  
475 represented as mean  $\pm$  SEM, \*= $p$ <0.05, \*\*= $p$ <0.01, \*\*\*= $p$ <0.001, \*\*\*\*= $p$ <0.0001,  
476 Student's t-test.

477 **Figure 4. Increasing cellular LD numbers acts to enhance the type I and III IFN**  
478 **response to dsRNA and dsDNA**

479 (a and b) Primary immortalised astrocyte cells were treated with 500µM oleic acid for 16  
480 hours, prior to stimulation with dsDNA or dsRNA. LDs numbers were assessed with ImageJ  
481 analysis software (greater than 200 cells, n=2) Bar, 15µm. (c) Primary immortalised astrocyte  
482 cells were treated with 500µM oleic acid for 16 hours prior to stimulation with dsDNA or  
483 dsRNA and analysed for LD numbers. RT-qPCR was performed to evaluate IFN- $\beta$ , IFN- $\lambda$   
484 and viperin mRNA expression at (d) 8 hours or (e) 24 hrs post stimulation. All results are in  
485 comparison to RPLPO expression (n=3). (f and g) IFN protein levels in the media from the  
486 previous experiments at 16 hours post infection were analysed with ELISA kits for IFN- $\beta$   
487 and IFN- $\lambda$  protein. Data is represented as mean  $\pm$  SEM, \*= $p$ <0.05, \*\*= $p$ <0.01,  
488 \*\*\*= $p$ <0.001, \*\*\*\*= $p$ <0.0001, Student's t-test for RT-PCRs and 2way multiple comparison  
489 ANOVA for ELISA experiments.



490

491 **Figure 5. Increasing cellular LD numbers enhances IFN responses to restrict ZIKV and**  
492 **HSV-1 viral replication**

493 Primary immortalised astrocyte cells were treated with 500  $\mu$ M oleic acid for 16 hours prior  
494 to infection with (a) ZIKV MR766 at MOI 0.1 or (b) HSV-1 at MOI 0.01. RT-qPCR was  
495 utilised to evaluate IFN- $\beta$ , IFN- $\lambda$  and viperin mRNA expression at 8, 24 and 48 hpi. Primary  
496 immortalised astrocyte cells were treated with 500  $\mu$ M oleic acid for 16 hours prior to  
497 infection with (c) ZIKV at a MOI 0.1 or (d) HSV-1 at an MOI 0.01, and RT-qPCR was  
498 utilised to evaluate viral replication at 6, 24 and 48 hpi. (e) At 16 hours post infection,  
499 secreted IFN protein levels from these experiments were analysed with ELISA plates for  
500 IFN-  $\beta$  and IFN- $\lambda$  protein. Data is represented as mean  $\pm$  SEM, n=3 biological replicates  
501 \*= $p$ <0.05, \*\*= $p$ <0.01, \*\*\*= $p$ <0.001, \*\*\*\*= $p$ <0.0001, Student's t-test for RT-PCRs and 2way  
502 multiple comparison ANOVA for ELISA experiments.

503 **Figure 6. Lipid droplet accumulation following intracellular nucleic acid detection is**  
504 **type I IFN Independent.**

505 (a) Vero cells were stimulated with dsRNA and dsDNA and were stained with Bodipy  
506 (409/505) to visualise LDs and DAPI to visualise the cell nuclei at 8 hours post stimulation.  
507 (b) Vero cells were fixed at 8, 24- and 48-hours post stimulation and analysed for LD  
508 numbers using ImageJ analysis software (greater than 200 cells (n=2)) Bars, 50 $\mu$ m. (c)  
509 Primary immortalised astrocyte cells were stimulated with either IFN-  $\beta$  or IFN- $\lambda$  for 8 hours  
510 prior to fixation and staining, and (d) LD analysis, all performed as above (greater than 200  
511 cells (n=2)). (e) Astrocyte cells were treated with pre-conditioned media from prior dsRNA  
512 or dsDNA stimulated astrocyte cells or were stimulated with 1000 U/mL of INF- $\beta$  and their  
513 LD numbers were analysed using ImageJ analysis software (greater than 200 cells (n=2)). (f)  
514 Astrocyte and Vero cells were treated with dsRNA or dsDNA conditioned media from either  
515 astrocytes or Vero cells and their LD numbers were analysed using ImageJ analysis software  
516 (greater than 200 cells (n=2)).

517 **Figure 7. LD Induction Following Nucleic Acid detection is EGFR Mediated**

518 Primary immortalised astrocyte cells were treated with 2 $\mu$ M AACOCF<sub>3</sub> (PLA<sub>2</sub> inhibitor) for  
519 16 hours prior to stimulation with dsRNA or dsDNA for 8 hours and (a) were stained with

520 Bodipy (409/505) to visualise LDs and DAPI to visualise the cell nuclei at 8 hour post  
521 stimulation, and **(b)** average numbers of LDs per cell was analysed using ImageJ analysis  
522 software (greater 200 cells, n=2). **(c)** Primary immortalised astrocyte cells were treated with  
523 2 $\mu$ M AG1478 (EGFR inhibitor) 16 hours prior to stimulation with dsRNA or dsDNA, or OA  
524 and were stained with Bodipy (409/505) to visualise LDs and DAPI to visualise the cell  
525 nuclei, and **(d)** average number of LDs per cell analysed using ImageJ analysis software  
526 (greater 200 cells, n=2). **(e)** Primary immortalised astrocyte cells were serum starved for 48  
527 hours, plated into wells and treated with 2  $\mu$ M AG-14789 or control for 16 hours. All cells  
528 were then given fresh full serum media for 36 hours and stained to visualise LDs as above. **(f)**  
529 Primary immortalised astrocyte cells were treated with 2 $\mu$ M AG-1478 (EGFR inhibitor) for  
530 16 hours prior to stimulation with dsRNA and dsDNA for up to 72 hours and were fixed at  
531 regular time points until 72 hours post stimulation. Average numbers of LDs per cell was  
532 analysed using ImageJ analysis software (greater than 200 cells, n=2). **(g)** Primary  
533 immortalised astrocyte cells were treated with 2  $\mu$ M AG-1478 (EGFR inhibitor) for 16 hours  
534 prior to stimulation with IFN- $\beta$  and their LDs were numbers assessed using image J analysis  
535 software. Bars, 50 $\mu$ m. Data is represented as mean  $\pm$  SEM, \*=p<0.05, \*\*=p<0.01,  
536 \*\*\*=p<0.001, \*\*\*\*=p<0.0001, Student's t-test.

537

538 **Figure 8. EGFR treatment enhances viral infection and dampens the interferon**  
539 **response to ZIKV and HSV-1**

540 Primary immortalised astrocyte cells were treated with 2  $\mu$ M AG-1478 (EGFR inhibitor) for  
541 16 hours prior to infection with ZIKV and HSV-1. RT-PCRs were performed to detect viral  
542 nucleic acid levels of **(a)** ZIKV and **(b)** HSV-1. RT-qPCR was utilised to evaluate IFN- $\beta$ ,  
543 IFN- $\lambda$  and viperin mRNA expression at 8, 24 and 48 hpi for both **(c)** ZIKV at MOI 0.1 or **(d)**  
544 HSV-1 at MOI 0.01. Data is represented as mean  $\pm$  SEM, n=3 biological replicates  
545 \*=p<0.05, \*\*=p<0.01, \*\*\*=p<0.001, \*\*\*\*=p<0.0001, Student's t-test.

546 **Methods**

547 **Cells and Culture Conditions**

548 All mammalian cell lines were maintained at 37°C in a 5% CO<sub>2</sub> air atmosphere. Huh-7  
549 human hepatoma cells, HeLa human epithelial cells, HEK293T human embryonic kidney

550 cells, primary murine embryonic fibroblast (MEF) cells, Vero cells, a green monkey kidney  
551 cell line, and Primary Immortalised Astrocytes were all maintained in DMEM (Gibco)  
552 containing 10% fetal bovine serum (FBS), 100 units/mL penicillin and 100 µg/mL  
553 streptomycin. Human monocytic cells (THP-1) were cultured in high glucose RPMI 1640  
554 medium, supplemented with 10% FBS, 100 units/mL penicillin and 100 µg/mL streptomycin.  
555 C6/36 *Aedes albopictus* cells were maintained in Basal Medium Eagle (BME) supplemented  
556 with L-glutamine, MEM non-essential amino acids, sodium pyruvate, 10% FBS and P/S and  
557 cultured at 28°C with 5% CO<sub>2</sub>. For serum replacement experiments, cells were cultured in  
558 serum replacement 3 (sigma, S 2640) in DMEM at a concentration of 10% prior to  
559 experiments. All experiments were then performed in serum replacement rather than  
560 DMEM+FBS.

### 561 **Influenza infection of mice**

562 C57BL/6 mice were bred in-house and housed under specific pathogen-free conditions in the animal  
563 facility at the Peter Doherty Institute of Infection and Immunity, University of Melbourne,  
564 Melbourne, Australia. All experiments were done in accordance with the Institutional Animal Care  
565 and Use Committee guidelines of the University of Melbourne. Mice were anesthetized with  
566 isoflurane and intranasally infected in a volume of 30 µL with 10<sup>4</sup> plaque forming units (PFU) of  
567 mouse adapted influenza A viruses, x31(H3N2) or PR8(H1N1). Mock infected mice received 30 µL  
568 of PBS intranasally.

569

### 570 ***In vitro* Viral Infection and Viral Mimics**

571 Monocytes were seeded at 1 x 10<sup>6</sup> per well in 12-well plates and pre-treated into polarisation  
572 states 24 hrs prior to infection with Influenza A Virus (IAV). Primary Immortalised Astrocyte  
573 cells were seeded at 7 x 10<sup>4</sup> per well in 12-well plates prior to infection with Herpes Simplex  
574 Virus-1 (HSV-1) and ZIKV (ZIKV). ZIKV (MR766 strain) and HSV-1 (KOS strain) were  
575 diluted in serum-free RPMI at a MOI of 0.1. Cells were washed once with PBS then infected  
576 with virus. IAV strains PR8 (H1N1) and X-31 (H3N2) were diluted in serum-free RPMI to a  
577 MOI of 1.0. THP-1 monocyte cells were seeded at 1–3 × 10<sup>6</sup> and were co-incubated with  
578 either PR8 or X-31 for 1 h in 200 µL AIM medium (RPMI 1640 medium supplemented with  
579 HCl to pH 6.0), followed by 8 h in 2 mL complete medium, RPMI 1640 medium  
580 supplemented with 10% fetal calf serum, at 37°C containing 5% CO<sub>2</sub>.

581 The viral mimics, poly dA: dT (dsDNA) and poly I: C (dsRNA) (Invivogen) were transfected  
582 into cells using PEI transfection reagent (Sigma-Aldrich, MO, USA) as per manufacturer's  
583 instructions at a concentration of 1  $\mu$ g/ml. For interferon stimulations, 1000 U/mL IFN- $\beta$   
584 (PBL Assays) and 100 ng/mL IFN- $\lambda$  (IL-29) (R&D Systems) were incubated on cells for 16 h  
585 (unless otherwise indicated).  
586

### 587 **Primary murine astrocyte cultures**

588 The establishment of astrocytic cultures from the brains of C57BL/6 mice (post-natal day 1.5)  
589 was performed as described previously<sup>58</sup>. Briefly, forebrains were dissected in ice-cold  
590 solution (Hanks balanced salt solution: 137 mM NaCl, 5.37 mM KCl, 4.1 mM NaHCO<sub>3</sub>, 0.44  
591 mM KH<sub>2</sub>PO<sub>4</sub>, 0.13 mM Na<sub>2</sub>HPO<sub>4</sub>, 10 mM HEPES, 1 mM sodium pyruvate, 13 mM  
592 d(+)-glucose, 0.01 g·L<sup>-1</sup> phenol red), containing 3 mg·mL<sup>-1</sup> BSA and 1.2 mM MgSO<sub>4</sub>, pH  
593 7.4). Cells were chemically and mechanically dissociated, centrifuged, and the pellet  
594 resuspended in astrocytic medium [AM: DMEM, Dulbecco's modified eagle medium, 10%  
595 FBS, 100 U·mL<sup>-1</sup> penicillin/streptomycin, 0.25% (v·v-1) Fungizone], preheated to 36.5°C at  
596 a volume of 5 mL per brain and plated at 10 mL per 75 cm<sup>2</sup> flask. Cells were maintained in a  
597 humidified incubator supplied with 5% CO<sub>2</sub> at 36.5°C and complete medium changes were  
598 carried out twice weekly. When a confluent layer had formed (~10 days *in vitro*), the cells  
599 were shaken overnight (180 rpm) and rinsed in fresh medium to remove non-astrocytic cells.  
600 Astrocytes were subsequently detached using 5 mM EDTA (10 min at 37°C), plated onto  
601 coverslips in 24-well plates at 1  $\times$  10<sup>4</sup> cells per well, and incubated in a humidified  
602 atmosphere at 36.5°C with 5% CO<sub>2</sub> overnight. A full medium change was performed to  
603 remove non-adherent cells and medium was subsequently changed every 3–4 days thereafter  
604 until cells were ready for use.

### 605 **Lipid droplet induction and treatments**

#### 606 For enhancing lipid droplets:

607 Oleic acid (n-9 MUFA, C18:1) - a Long-chain fatty acid was used to increase LDs within  
608 cells. OA was purchased from Sigma (Sigma-Aldrich, MO, USA) and dissolved in 0.1%  
609 NaOH and 10% bovine serum albumin (BSA). OA was prepared as a 10 mM stock solution  
610 and stored at -20°C. BSA was used as a vehicle control. Cells were treated with 500  $\mu$ M OA  
611 in DMEM (+1% BSA) for 16 h.

612 *For Serum Starvation of cells:*

613 Cells were either given low serum media containing 2% FCS, or control serum media  
614 containing 10% FCS and were incubated in T75cm<sup>2</sup> flasks for 48 hours prior to plating at the  
615 required cell density as previously described<sup>19</sup>. Cell culture media on all experiments was  
616 changed 30 minutes prior to the beginning of the experiment, with all transfections and  
617 experiments being performed in 10% FCS.

618 *Inhibition of EGFR*

619 Tyrphostin AG1478 (4-(3-chloroanilino-6, 7-dimethoxyquinazoline) mesylate, Mr 411.1) was  
620 manufactured by the Institute of Drug Technology (IDT, Melbourne, Australia) and  
621 solubilized in DMSO (stock 50 mM). Cells were grown in media containing 2 μM AG1478  
622 or an equivalent amount of vehicle (DMSO, 1:25,000 v/v). In all experiments AG1478 media  
623 was discarded, and the cells were washed twice with 1x PBS before being followed in pre-  
624 warmed media without AG1478 1 h prior to infection/stimulation.

625 *Inhibition of PLA<sub>2</sub>*

626 AACOCF<sub>3</sub> (Abcam; ab120350) was utilised to inhibit PLA<sub>2</sub>. AACOCF<sub>3</sub> was prepared in  
627 DMSO and stored at -20°C. Aliquots were diluted in complete DMEM to 2 μM immediately  
628 prior to use. The final DMSO concentration was always lower than 0.1% and had no effect on  
629 lipid droplet numbers.

630 *Inhibition of PI3K*

631 Wortmannin is a well-described inhibitor of PI3K<sup>59</sup> and was obtained from Sigma, dissolved  
632 in DMSO at a concentration of 1 mM. Cells were grown in media containing 100 μM  
633 Wortmannin. In all experiments, Wortmannin media was discarded, and the cells were  
634 washed twice with PBS before addition of pre-warmed media without Wortmannin 1 h prior  
635 to infection/stimulation.

636 **IFN ELISAs**

637 Cell culture supernatant was analysed for IFN-β and IFN-λ release using commercial ELISA  
638 kits (Crux Biolab, Human IFN-beta ELISA kit (EK-0041) and RayBiotech inc., Human IL-29  
639 ELISA (ELH-IL29-1)) following the manufacturer's instructions.

## 640 **Conditioned IFN media experiments**

641 Primary immortalised astrocyte cells or Vero cells were stimulated with dsRNA and dsDNA  
642 viral mimics for 4 hours before being washed and replenished with fresh complete DMEM  
643 media and left to produce IFNs for a further 12 hours. Media was then taken from these cells,  
644 centrifuged to remove any cell debris and placed on freshly seeded unstimulated cells. These  
645 cells were left in this conditioned media for 8 hours and fixed with 4% paraformaldehyde  
646 (PFA) and their LD numbers were analysed.

## 647 **Immunofluorescence Microscopy**

648 Bodipy staining for LDs was performed as previously described<sup>19</sup>. For cultured cells, briefly,  
649 cells were grown in 24-well plates on 12 mm glass coverslips coated with gelatine (0.2%  
650 [v/v]) were washed with PBS, fixed with 4% paraformaldehyde in PBS for 15 min at room  
651 temperature and permeabilised with 0.1% Triton X-100 in PBS for 10 min. For staining of  
652 LDs, cells were incubated with Bodipy 409/505 1 ng/mL for 1 h and then incubated with  
653 DAPI (Sigma-Aldrich, 1 µg/ml) for 5 min at room temperature. Samples were then washed  
654 with PBS and mounted with Vectashield Antifade Mounting Medium (Vector Laboratories).  
655 Preparation and staining of murine lung frozen sections was done as previously described<sup>60</sup>.  
656 Briefly, frozen lung sections were prepared by inflating the lungs with optimum cutting  
657 temperature (OCT). Frozen sections were cut at 14 µM with a Leica CM 3050 S cryostat and  
658 mounted on microscope slides and stored at -80°C. Sections were fixed with 4%  
659 paraformaldehyde in PBS for 15 min at room temperature. Sections were then washed with  
660 PBS, permeabilised with 0.1% Triton X-100 in PBS for 10 min, washed again and then  
661 blocked with 1% BSA for 30 mins. Sections were incubated with 1:1000 αIAV NP for 1  
662 hour. Sections were then washed and incubated with Alexa Fluor 555 secondary antibody at  
663 1:200 for 1 hour. Bodipy was used to stain for lipid droplets at 1 ng/mL for 1 hour at room  
664 temperature, and nuclei were stained with DAPI for 5 minutes at room temperature. Images  
665 were then acquired using either a Nikon TiE inverted fluorescence microscope or ZEISS  
666 confocal microscope. Unless otherwise indicated images were processed using NIS Elements  
667 AR v.3.22. (Nikon) and ImageJ analysis software.

## 668 **Lipid Droplet enumeration**

669 LD numbers and diameters were analysed using quantitative data from the raw ND2 images  
670 (from NIS elements) in ImageJ using the particle analysis tool. For each condition, at least 9

671 fields of view were imaged at 60X magnification from different locations across each  
672 coverslip. LDs from at least 100 cells per biological replicate with a minimum of n=2 per  
673 experiment being analysed for both LD number and average LD size.

#### 674 **RNA Extraction and Real Time PCR**

675 All experiments involving real-time PCR were performed in 12-well plates with cells seeded  
676 at  $1 \times 10^6$ /well (monocytes and macrophages) or  $7 \times 10^4$ /well (all other cell types) 24 hrs prior  
677 to infections/stimulations and performed at least in triplicate. Total RNA was extracted from  
678 cells using TriSure reagent (Bioline), with first strand cDNA being synthesized from total  
679 RNA and reverse transcribed using a Tetro cDNA synthesis kit (Bioline). Quantitative real-  
680 time PCR was performed in a CFX Connect Real-Time Detection System (BioRad) to  
681 quantitate the relative levels of IFN and interferon stimulated gene mRNA in comparison to  
682 the housekeeping gene RPLPO. Primers sequences were as follows: RPLPO-FP 5'-AGA  
683 TGC AGC AGA TCC GCA T-3', RPLPO-RP 5'-GGA TGG CCT TGC GCA-3', IFN- $\beta$ -FP  
684 5'-AGA AAG GAC GAA CAT TGG GAA A-3', IFN- $\beta$ -RP 5'-TAG CAG AGC CCT TTT  
685 TGA TAA TGT AA-3', IFN- $\lambda$  -FP 5'-GAA GAG TCA CTC AAG CTG AAA AAC-3', IFN-  
686  $\lambda$ -RP 5'-AGA AGC CTC AGG TCC CAA TTC-3', Viperin-FP 5'GTG AGC AAT GGA  
687 AGC CTG ATC-3' , Viperin-RP 5'-GCT GTC ACA GGA GAT AGC GAG AA-3', ZIKV-  
688 FP 5'CAG CTG GCA TCA TGA AGA AGA AYC-3', ZIKV-RP 5'CAC YTG TCC CAT  
689 CTT YTT CTC C-3', HSV-1 5'-TCG GCG TGG AAG AAA CGA GAG A-3' and HSV-1  
690 5'-CGA ACG CAC CCA AAT CGA CA-3'.

#### 691 **Statistical Analysis**

692 Results are expressed as mean  $\pm$  SEM. Student's t tests were used for statistical analysis  
693 between 2 groups, with  $p < 0.05$  considered to be significant. Experiments with 2 or more  
694 experimental groups were statistically analysed using an ordinary two-way ANOVA with  
695 multiple comparisons. All statistical analysis was performed using Prism 8 (GraphPad  
696 Software). All experiments were performed in biological triplicate (unless otherwise stated),  
697 and technical duplicates for RT-PCRs.

698

#### 699 **Supplemental Information titles and legends**

700 **Supplementary Figure 1. Influenza, ZIKV and HSV-1 virus infection stimulated the**  
701 **induction of lipid droplets**

702 (a) Human THP-1 monocytes were infected with two different strains of influenza- PR8 and  
703 X-31 at MOI 5. Primary immortalised astrocyte cells were infected with either the ZIKV  
704 strain MR766 or HSV-1 at MOI 5 and stained with Bodipy (409/505) to visualise lipid  
705 droplets and DAPI to visualise the cell nuclei. Influenza virus was detected with a  $\alpha$ NS2  
706 antibody, ZIKV RNA was detected using an anti-3G1.1 and 2G4 dsRNA antibody and HSV-  
707 1 was detected using the anti-HSV-1 antibody ab9533. Bars, 50 $\mu$ m (b) C57BL/6 mice were  
708 either mock infected or infected with influenza A virus for either 1 or 3 days prior to removal  
709 of both lung lobes for immunofluorescence analysis of lipid droplets via Bodipy staining.  
710 Figures represent 3 replicate lung sections. Bars, 50 $\mu$ m

711 **Supplementary Figure 2. Lipid droplets accumulate in multiple cell types in response to**  
712 **detection of dsRNA and dsDNA.**

713 (a) Primary murine astrocyte, HeLa, THP-1 macrophages and MEF cells were stimulated  
714 with dsRNA and dsDNA for 8hrs and stained with Bodipy (409/505) to visualise lipid  
715 droplets and DAPI to visualise the cell nuclei. Cells were imaged on a Nikon TiE  
716 microscope. Original magnification is 60X. (b) To assess if this induction was dependant on  
717 fetal calf serum in the cell media primary immortalised astrocyte cells were grown in serum  
718 replacement media, seeded on coverslips and stimulated with dsRNA and dsDNA for 8  
719 hours. Cells were stained with Bodipy (409/505) to visualise lipid droplets and DAPI to  
720 visualise the cell nuclei, and average number of lipid droplets per cell analysed using ImageJ  
721 analysis software (greater 200 cells, n=2). \*\*\*\*= $p < 0.0001$ , Student's t-test. Bars, 50 $\mu$ m.

722 **Supplementary Figure 3. The average size of lipid droplet increases following detection**  
723 **of dsRNA and dsDNA and return to basal sizes at 72 hours.**

724 Primary immortalised astrocyte cells were stimulated with dsRNA and dsDNA and were  
725 fixed at regular time points until 72 hours post stimulation. Cells were stained with Bodipy  
726 (409/505) to visualise lipid droplets and DAPI to visualise the cell nuclei. (a) Average size  
727 (diameter) of lipid droplets per cell were analysed from all time points using ImageJ analysis  
728 software (greater 200 cells, n=2) \*= $p < 0.05$ , \*\*= $p < 0.01$ , \*\*\*= $p < 0.001$ , \*\*\*\*= $p < 0.0001$ ,  
729 Student's t-test.



730 **Supplementary Figure 4. Lipid droplets continue to accumulate following dsRNA and**  
731 **dsDNA after oleic acid treatment**

732 Primary immortalised astrocyte cells were treated with 500 $\mu$ M oleic acid for 16 hours, prior  
733 to stimulation with dsDNA or dsRNA. (a) Lipid droplets numbers were assessed with ImageJ  
734 analysis software (greater than 200 cells, n=2). Bars, 50 $\mu$ m

735 **Supplementary Figure 5. The average size of lipid droplet increases following detection**  
736 **of dsRNA and dsDNA in Vero cells**

737 Vero cells were stimulated with dsRNA and dsDNA and were stained with Bodipy (409/505)  
738 to visualise lipid droplets and DAPI to visualise the cell nuclei at 8, 24 and 48 hours post  
739 stimulation and (a) analysed for lipid droplet sizes (diameters) using ImageJ analysis  
740 software (greater than 200 cells (n=2)) \*=p<0.05, \*\*=p<0.01, \*\*\*=p<0.001, \*\*\*\*=p<0.0001,  
741 Student's t-test.

742 **Supplementary Figure 6. AACOCF<sub>3</sub> treatment inhibits the homeostatic biogenesis of**  
743 **lipid droplets.**

744 (a) Primary immortalised astrocyte cells were treated with 2 $\mu$ M AACOCF<sub>3</sub> for 16 hours and  
745 LD numbers were compared to control treated cells using ImageJ analysis software (greater  
746 than 200 cells (n=2)). (b) Primary immortalised astrocyte cells were serum starved for 48  
747 hours, plated into wells and treated with 2 $\mu$ M AACOCF<sub>3</sub> (PLA<sub>2</sub> inhibitor) or left as control  
748 cells for 16 hours. All cells were then given fresh full serum media for 36 hours and stained  
749 with Bodipy (409/505) to visualise lipid droplets and DAPI to visualise the cell nuclei, and  
750 average number of lipid droplets per cell analysed using ImageJ analysis software (greater  
751 200 cells, n=2). Bars, 50 $\mu$ m.

752 **Supplementary Figure 7. EGFR and PI3K control the induction of virally induced LDs**

753 (a) MCF-7 cells (known to lack EGFR) were stimulated with dsRNA and dsDNA for 8 hours  
754 and visualised for lipid droplet content and (b) analysed using ImageJ analysis software  
755 (greater than 200 cells (n=2)). (c) Primary immortalised astrocyte cells were stimulated with  
756 Wortmannin (PI3K inhibitor) and stimulated with dsRNA and dsDNA and their LD numbers  
757 were analysed using ImageJ analysis software (greater than 200 cells (n=2)) \*=p<0.05,  
758 \*\*=p<0.01, \*\*\*=p<0.001, \*\*\*\*=p<0.0001, Student's t-test. Bars, 50 $\mu$ m.

759 **Supplementary Figure 8. AG1478 treatment reduces type I and III IFN production in**  
760 **primary immortalised astrocyte cells following dsRNA and dsDNA stimulation**

761 (a) Primary immortalised astrocyte cells were treated with 2 $\mu$ M AG1478 (EGFR inhibitor)  
762 for 16 hours prior to stimulation with dsDNA or dsRNA and RT-qPCR was performed to  
763 evaluate IFN- $\beta$ , IFN- $\lambda$  and viperin mRNA expression at 8 hours and 24 hrs post stimulation.

764 **Supplementary Figure 9. LDs are induced upon initial ZIKV infection, but are**  
765 **downregulated by 48 hours post infection**

766 (a) Primary immortalised astrocyte cells were infected with ZIKV strain MR766 at MOI 5 for  
767 up to 72 hours post infection. Cells were stained with Bodipy (409/505) to visualise lipid  
768 droplets and DAPI to visualise the cell nuclei, ZIKV RNA was detected using an anti-3G1.1  
769 and 2G4 dsRNA antibody (b) the average number of LDs was analysed per cell with ImageJ  
770 analysis software (greater 200 cells, n=2) \*\*\*\*=p<0.0001, Student's t-test. Bars, 50 $\mu$ m.

771

772 **References**

- 773 1. Arrese, E. L., Saudale, F. Z. & Soulages, J. L. Lipid Droplets as Signaling Platforms Linking  
774 Metabolic and Cellular Functions. *Lipid Insights* **7**, 7–16 (2014).
- 775 2. den Brok, M. H., Raaijmakers, T. K., Collado-Camps, E. & Adema, G. J. Lipid Droplets as  
776 Immune Modulators in Myeloid Cells. *Trends Immunol.* **39**, 380–392 (2018).
- 777 3. Gao, Q. & Goodman, J. M. The lipid droplet-a well-connected organelle. *Front Cell Dev Biol* **3**,  
778 49 (2015).
- 779 4. Henne, W. M., Reese, M. L. & Goodman, J. M. The assembly of lipid droplets and their roles in  
780 challenged cells. *EMBO J.* **38**, (2019).
- 781 5. Mattos, K. A. *et al.* Modulation of lipid droplets by *Mycobacterium leprae* in Schwann cells: a  
782 putative mechanism for host lipid acquisition and bacterial survival in phagosomes. *Cell.*  
783 *Microbiol.* **13**, 259–273 (2011).
- 784 6. Rank, R. G., Whittimore, J., Bowlin, A. K. & Wyrick, P. B. In vivo ultrastructural analysis of the  
785 intimate relationship between polymorphonuclear leukocytes and the chlamydial developmental


- 786 cycle. *Infect. Immun.* **79**, 3291–3301 (2011).
- 787 7. Nicolaou, G., Goodall, A. H. & Erridge, C. Diverse bacteria promote macrophage foam cell  
788 formation via Toll-like receptor-dependent lipid body biosynthesis. *J. Atheroscler. Thromb.* **19**,  
789 137–148 (2012).
- 790 8. D’Avila, H. *et al.* Host Cell Lipid Bodies Triggered by Trypanosoma cruzi Infection and  
791 Enhanced by the Uptake of Apoptotic Cells Are Associated With Prostaglandin E2 Generation  
792 and Increased Parasite Growth. *The Journal of Infectious Diseases* vol. 204 951–961 (2011).
- 793 9. Tanigawa, K. *et al.* Expression of adipose differentiation-related protein (ADRP) and perilipin in  
794 macrophages infected with Mycobacterium leprae. *FEMS Microbiol. Lett.* **289**, 72–79 (2008).
- 795 10. Pacheco, P. *et al.* Lipopolysaccharide-induced leukocyte lipid body formation in vivo: innate  
796 immunity elicited intracellular Loci involved in eicosanoid metabolism. *J. Immunol.* **169**, 6498–  
797 6506 (2002).
- 798 11. Dutta, A., Banerjee, S. & Sinha, D. K. Lipid Droplet metabolism dependent microbial defense in  
799 pre-immune zebrafish embryos. *bioRxiv* 478859 (2018) doi:10.1101/478859.
- 800 12. Anand, P. *et al.* A novel role for lipid droplets in the organismal antibacterial response. *Elife* **1**,  
801 e00003 (2012).
- 802 13. Knight, M., Braverman, J., Asfaha, K., Gronert, K. & Stanley, S. Lipid droplet formation in  
803 Mycobacterium tuberculosis infected macrophages requires IFN- $\gamma$ /HIF-1 $\alpha$  signaling and supports  
804 host defense. *PLoS Pathog.* **14**, e1006874 (2018).
- 805 14. Truong, N., Love-Rutledge, S., Lydic, T. & Olson, L. K. Effect of interferon gamma on neutral  
806 lipid levels, lipid droplet formation, and antiviral responses in pancreatic islets and INS-1  $\beta$  cells.  
807 *The FASEB Journal* **33**, 654.11–654.11 (2019).
- 808 15. Barletta, A. B. F. *et al.* Emerging role of lipid droplets in Aedes aegypti immune response  
809 against bacteria and Dengue virus. *Sci. Rep.* **6**, 19928 (2016).
- 810 16. Weed, D. J. & Nicola, A. V. Herpes simplex virus Membrane Fusion. *Cell Biology of Herpes*  
811 *Viruses* 29–47 (2017) doi:10.1007/978-3-319-53168-7\_2.
- 812 17. Cohen, F. S. How Viruses Invade Cells. *Biophysical Journal* vol. 110 1028–1032 (2016).
- 813 18. Pol, A., Gross, S. P. & Parton, R. G. Review: biogenesis of the multifunctional lipid droplet:

- 814 lipids, proteins, and sites. *J. Cell Biol.* **204**, 635–646 (2014).
- 815 19. Monson, E. A., Crosse, K. M., Das, M. & Helbig, K. J. Lipid droplet density alters the early  
816 innate immune response to viral infection. *PLoS One* **13**, e0190597 (2018).
- 817 20. Rohwedder, A., Zhang, Q., Rudge, S. A. & Wakelam, M. J. O. Lipid droplet formation in  
818 response to oleic acid in Huh-7 cells is mediated by the fatty acid receptor FFAR4. *J. Cell Sci.*  
819 **127**, 3104–3115 (2014).
- 820 21. Roers, A., Hiller, B. & Hornung, V. Recognition of Endogenous Nucleic Acids by the Innate  
821 Immune System. *Immunity* **44**, 739–754 (2016).
- 822 22. Desmyter, J., Melnick, J. L. & Rawls, W. E. Defectiveness of interferon production and of  
823 rubella virus interference in a line of African green monkey kidney cells (Vero). *J. Virol.* **2**, 955–  
824 961 (1968).
- 825 23. Mosca, J. D. & Pitha, P. M. Transcriptional and posttranscriptional regulation of exogenous  
826 human beta interferon gene in simian cells defective in interferon synthesis. *Mol. Cell. Biol.* **6**,  
827 2279–2283 (1986).
- 828 24. Gubern, A. *et al.* Group IVA phospholipase A2 is necessary for the biogenesis of lipid droplets.  
829 *J. Biol. Chem.* **283**, 27369–27382 (2008).
- 830 25. Penrose, H. *et al.* Epidermal growth factor receptor mediated proliferation depends on increased  
831 lipid droplet density regulated via a negative regulatory loop with FOXO3/Sirtuin6. *Biochem.*  
832 *Biophys. Res. Commun.* **469**, 370–376 (2016).
- 833 26. Johns, T. G. *et al.* Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is  
834 enhanced by the EGF receptor inhibitor AG1478. *Proc. Natl. Acad. Sci. U. S. A.* **100**, 15871–  
835 15876 (2003).
- 836 27. Miller, D. L. *et al.* Emergence of MCF-7 cells overexpressing a transfected epidermal growth  
837 factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in  
838 breast cancer growth and progression. *Cell Growth Differ.* **5**, 1263–1274 (1994).
- 839 28. Zhang, J. *et al.* Flaviviruses Exploit the Lipid Droplet Protein AUP1 to Trigger Lipophagy and  
840 Drive Virus Production. *Cell Host Microbe* **23**, 819–831.e5 (2018).
- 841 29. Leier, H. C., Messer, W. B. & Tafesse, F. G. Lipids and pathogenic flaviviruses: An intimate

- 842 union. *PLoS Pathog.* **14**, e1006952 (2018).
- 843 30. Zhang, J., Lan, Y. & Sanyal, S. Modulation of Lipid Droplet Metabolism-A Potential Target for  
844 Therapeutic Intervention in Flaviviridae Infections. *Front. Microbiol.* **8**, 2286 (2017).
- 845 31. Laufman, O., Perrino, J. & Andino, R. Viral Generated Inter-Organelle Contacts Redirect Lipid  
846 Flux for Genome Replication. *Cell* **178**, 275–289.e16 (2019).
- 847 32. Thiam, A. R. & Beller, M. The why, when and how of lipid droplet diversity. *J. Cell Sci.* **130**,  
848 315–324 (2017).
- 849 33. Lindqvist, R. *et al.* Fast type I interferon response protects astrocytes from flavivirus infection  
850 and virus-induced cytopathic effects. *J. Neuroinflammation* **13**, 277 (2016).
- 851 34. Furr, S. R. & Marriott, I. Viral CNS infections: role of glial pattern recognition receptors in  
852 neuroinflammation. *Front. Microbiol.* **3**, 201 (2012).
- 853 35. Li, J. *et al.* Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes  
854 and neurons. *Glia* **59**, 58–67 (2011).
- 855 36. Sorgeloos, F., Kreit, M., Hermant, P., Lardinois, C. & Michiels, T. Antiviral type I and type III  
856 interferon responses in the central nervous system. *Viruses* **5**, 834–857 (2013).
- 857 37. Jackson, C. L. Lipid droplet biogenesis. *Current Opinion in Cell Biology* vol. 59 88–96 (2019).
- 858 38. Chapman, K. D., Aziz, M., Dyer, J. M. & Mullen, R. T. Mechanisms of lipid droplet biogenesis.  
859 *Biochem. J* **476**, 1929–1942 (2019).
- 860 39. Tan, J. S. Y., Seow, C. J. P., Goh, V. J. & Silver, D. L. Recent advances in understanding  
861 proteins involved in lipid droplet formation, growth and fusion. *J. Genet. Genomics* **41**, 251–259  
862 (2014).
- 863 40. Olzmann, J. A. & Carvalho, P. Dynamics and functions of lipid droplets. *Nat. Rev. Mol. Cell*  
864 *Biol.* **20**, 137–155 (2019).
- 865 41. Lupberger, J. *et al.* Epidermal growth factor receptor signaling impairs the antiviral activity of  
866 interferon-alpha. *Hepatology* **58**, 1225–1235 (2013).
- 867 42. Ueki, I. F., Min-Oo, G. & Kalinowski, A. Respiratory virus-induced EGFR activation suppresses  
868 IRF1-dependent interferon  $\lambda$  and antiviral defense in airway epithelium. *Journal of* (2013).
- 869 43. Lulli, D., Carbone, M. L. & Pastore, S. Epidermal growth factor receptor inhibitors trigger a type


- 870 I interferon response in human skin. *Oncotarget* **7**, 47777–47793 (2016).
- 871 44. Helbig, K. J. & Beard, M. R. The role of viperin in the innate antiviral response. *J. Mol. Biol.*  
872 **426**, 1210–1219 (2014).
- 873 45. Helbig, K. J. *et al.* Viperin is induced following dengue virus type-2 (DENV-2) infection and has  
874 anti-viral actions requiring the C-terminal end of viperin. *PLoS Negl. Trop. Dis.* **7**, e2178 (2013).
- 875 46. Helbig, K. J. *et al.* The antiviral protein viperin inhibits hepatitis C virus replication via  
876 interaction with nonstructural protein 5A. *Hepatology* **54**, 1506–1517 (2011).
- 877 47. Crosse, K. M. *et al.* Viperin binds STING and enhances the type-I interferon response following  
878 dsDNA detection. *bioRxiv* 493098 (2019) doi:10.1101/493098.
- 879 48. Saitoh, T. *et al.* Antiviral protein Viperin promotes Toll-like receptor 7- and Toll-like receptor 9-  
880 mediated type I interferon production in plasmacytoid dendritic cells. *Immunity* **34**, 352–363  
881 (2011).
- 882 49. Hubler, M. J. & Kennedy, A. J. Role of lipids in the metabolism and activation of immune cells.  
883 *J. Nutr. Biochem.* **34**, 1–7 (2016).
- 884 50. Antonyak, M. A., Lukey, M. J. & Cerione, R. A. Lipid-filled vesicles modulate macrophages.  
885 *Science* vol. 363 931–932 (2019).
- 886 51. Dennis, E. A. & Norris, P. C. Eicosanoid storm in infection and inflammation. *Nat. Rev.*  
887 *Immunol.* **15**, 511–523 (2015).
- 888 52. Serhan, C. N. Pro-resolving lipid mediators are leads for resolution physiology. *Nature* **510**, 92–  
889 101 (2014).
- 890 53. Jarc, E. & Petan, T. A twist of FATE: Lipid droplets and inflammatory lipid mediators.  
891 *Biochimie* (2019) doi:10.1016/j.biochi.2019.11.016.
- 892 54. Morita, M. *et al.* The lipid mediator protectin D1 inhibits influenza virus replication and  
893 improves severe influenza. *Cell* **153**, 112–125 (2013).
- 894 55. Beller, M. *et al.* Characterization of the *Drosophila* lipid droplet subproteome. *Mol. Cell.*  
895 *Proteomics* **5**, 1082–1094 (2006).
- 896 56. Hsieh, K. *et al.* Perilipin family members preferentially sequester to either triacylglycerol-  
897 specific or cholesteryl-ester-specific intracellular lipid storage droplets. *J. Cell Sci.* **125**, 4067–

- 898 4076 (2012).
- 899 57. Martin, S., Driessen, K., Nixon, S. J., Zerial, M. & Parton, R. G. Regulated localization of Rab18  
900 to lipid droplets: effects of lipolytic stimulation and inhibition of lipid droplet catabolism. *J. Biol.*  
901 *Chem.* **280**, 42325–42335 (2005).
- 902 58. O’Shea, R. D. *et al.* Effects of lipopolysaccharide on glial phenotype and activity of glutamate  
903 transporters: Evidence for delayed up-regulation and redistribution of GLT-1. *Neurochem. Int.*  
904 **48**, 604–610 (2006).
- 905 59. Hansen, S. H., Olsson, A. & Casanova, J. E. Wortmannin, an inhibitor of phosphoinositide 3-  
906 kinase, inhibits transcytosis in polarized epithelial cells. *J. Biol. Chem.* **270**, 28425–28432  
907 (1995).
- 908 60. Zhou, X. & Moore, B. B. Lung Section Staining and Microscopy. *Bio Protoc* **7**, (2017).
- 909










## Figure 2



# Figure 3

bioRxiv preprint doi: <https://doi.org/10.1101/2020.02.12.946749>; this version posted February 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license.






**Figure 5**


**A**

**Zika Virus Infection**




**B**

**HSV-1 Infection**




**C**

**Zika Replication**




**D**

**HSV-1 Replication**




**E**

**IFN- $\beta$**




**IFN- $\lambda$**




# Figure 6

bioRxiv preprint doi: <https://doi.org/10.1101/2020.02.12.946749>; this version posted February 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license.




# Figure 7




**Figure 8**

**A**






**B**



## Zika Virus Infection

**C**



**D**

